22 analysts have expressed a variety of opinions on Kymera Therapeutics (NASDAQ:KYMR) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 10 | 12 | 0 | 0 | 0 |
| Last 30D | 1 | 1 | 0 | 0 | 0 |
| 1M Ago | 1 | 1 | 0 | 0 | 0 |
| 2M Ago | 1 | 0 | 0 | 0 | 0 |
| 3M Ago | 7 | 10 | 0 | 0 | 0 |
Analysts have set 12-month price targets for Kymera Therapeutics, revealing an average target of $123.41, a high estimate of $140.00, and a low estimate of $103.00. This upward trend is evident, with the current average reflecting a 40.38% increase from the previous average price target of $87.91.
Interpreting Analyst Ratings: A Closer Look
An in-depth analysis of recent analyst actions unveils how financial experts perceive Kymera Therapeutics. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Jeet Mukherjee | BTIG | Lowers | Buy | $134.00 | $138.00 |
| Biren Amin | Piper Sandler | Raises | Overweight | $140.00 | $125.00 |
| Jeet Mukherjee | BTIG | Maintains | Buy | $138.00 | $138.00 |
| Etzer Darout | Barclays | Raises | Overweight | $133.00 | $119.00 |
| Jeet Mukherjee | BTIG | Maintains | Buy | $138.00 | $138.00 |
| Kalpit Patel | B. Riley Securities | Raises | Buy | $117.00 | $80.00 |
| Brian Abrahams | RBC Capital | Raises | Outperform | $103.00 | $70.00 |
| Sudan Loganathan | Stephens & Co. | Raises | Overweight | $110.00 | $65.00 |
| Joseph Catanzaro | Mizuho | Raises | Outperform | $120.00 | $81.00 |
| Brian Cheng | JP Morgan | Raises | Overweight | $125.00 | $70.00 |
| Kelly Shi | Jefferies | Raises | Buy | $122.00 | $73.00 |
| Geoff Meacham | Citigroup | Raises | Buy | $110.00 | $80.00 |
| Derek Archila | Wells Fargo | Raises | Overweight | $116.00 | $69.00 |
| Srikripa Devarakonda | Truist Securities | Raises | Buy | $116.00 | $80.00 |
| Jeff Jones | Oppenheimer | Raises | Outperform | $120.00 | $67.00 |
| James Quigley | Morgan Stanley | Raises | Overweight | $127.00 | $73.00 |
| Etzer Darout | Barclays | Raises | Overweight | $119.00 | $70.00 |
| Edward Tenthoff | Piper Sandler | Raises | Overweight | $125.00 | $98.00 |
| Andrew S. Fein | HC Wainwright & Co. | Raises | Buy | $134.00 | $84.00 |
| Faisal Khurshid | Leerink Partners | Raises | Outperform | $118.00 | $70.00 |
| Tazeen Ahmad | B of A Securities | Raises | Buy | $112.00 | $71.00 |
| Jeet Mukherjee | BTIG | Raises | Buy | $138.00 | $75.00 |
Key Insights:
- Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Kymera Therapeutics. This offers insight into analysts' perspectives on the current state of the company.
- Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Kymera Therapeutics compared to the broader market.
- Price Targets: Delving into movements, analysts provide estimates for the future value of Kymera Therapeutics's stock. This analysis reveals shifts in analysts' expectations over time.
Capture valuable insights into Kymera Therapeutics's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
Stay up to date on Kymera Therapeutics analyst ratings.
About Kymera Therapeutics
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of, differentiated medicines that address health problems and that meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, TYK2, and IRAK4.
Kymera Therapeutics: A Financial Overview
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Decline in Revenue: Over the 3M period, Kymera Therapeutics faced challenges, resulting in a decline of approximately -26.12% in revenue growth as of 30 September, 2025. This signifies a reduction in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of -2973.05%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of -8.57%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Kymera Therapeutics's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -7.36%, the company may face hurdles in achieving optimal financial performance.
Debt Management: Kymera Therapeutics's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.09.
How Are Analyst Ratings Determined?
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
- No comments yet. Be the first to comment!